2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thromboembolism, Thrombotic Disorders, VWD, Genetic Disorders, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5546 Burden of chronic health conditions among survivors of Erdheim-Chester disease: Findings from a national survivorship cohort

Jacquelyn Elise Fitzgerald Fitzgerald, BS, Caroline Cannon2, Luqin Deng3, Brinda Shukla4, Ronald Go, MD5, Jithma Abeykoon, MD6, Lindsey Hageman, MPH7, Jennifer Silvers8, Kathleen Brewer9, Belinda Cobb10, Smita Bhatia, MD, MPH11, Gaurav Goyal, MD12
1 University of Alabama at Birmingham, Birmingham, Alabama, United States
2 University of Alabama at Birmingham, Birmingham, Alabama, United States
3 University of Alabama at Birmingham, Birmingham, Alabama, United States
4 University of Alabama at Birmingham, Birmingham, Alabama, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 University of Alabama at Birmingham, Birmingham, Alabama, United States
8 Histiocytosis Association, Pitman, New Jersey, United States
9 Erdheim-Chester Disease Global Alliance, DeRidder, Louisiana, United States
10 Erdheim-Chester Disease Global Alliance, DeRidder, Louisiana, United States
11 University of Alabama at Birmingham, Birmingham, Alabama, United States
12 University of Alabama at Birmingham, Birmingham, Alabama, United States

Background: The use of targeted BRAF- and MEK-inhibitors has improved disease-specific survival in Erdheim-Chester disease (ECD). As a result, more individuals are living with the long-term effects of both the disease and chronic treatment. Despite these advances, little is known about the chronic health conditions that develop after ECD diagnosis. We evaluated the burden of chronic health conditions among adults with ECD enrolled in a national survivorship cohort.

Methods: The Histiocytic Disorder Survivorship Study (HDSS; NCT05915208) was established in 2022 through a collaboration between the University of Alabama at Birmingham and two patient support organizations (the Erdheim-Chester Disease Global Alliance and the Histiocytosis Association). Participants completed a detailed survey reporting clinician-diagnosed chronic health conditions (including second malignancies) and the timing of each diagnosis. Chronic conditions were graded using a survivorship-specific severity scale based on the Common Terminology Criteria for Adverse Events (CTCAE) (grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening or disabling). The survey completion rate was 71%. Adults with ECD who completed the survey were included in this analysis. Of 159 eligible adults with ECD, 126 met inclusion criteria of being at least 1 year post-diagnosis. We examined prevalent chronic health conditions at the most recent follow-up and new-onset/incident chronic health conditions occurring more than one year after ECD diagnosis. A subset of participants also underwent medical record review to validate self-reported conditions and diagnoses.

Results: The study included 126 adults with ECD. Median age at diagnosis was 54 years (IQR 46-60), 64.3% were male, and 60.3% had a BRAF V600E mutation. Median follow-up after diagnosis was 5 years (IQR 2-9). The most commonly affected organ systems at diagnosis were bone (69.1%), kidney (49.2%), brain/CNS (42.9%), eyes (31.0%), heart (27.0%), lungs (25.4%), and aorta or other vascular structures (23.0%). At last follow-up, 79.4% of participants reported at least one chronic health condition, and 39.7% reported at least one severe/life-threatening (grade 3-4) chronic health condition. New/incident chronic health conditions occurring ≥1 year after ECD diagnosis were reported by 71.4% of participants, with 33.3% experiencing at least one new severe/life-threatening (grade 3-4) condition. The most frequently reported incident chronic health conditions involved the neurologic (28.6%), vision (24.6%), endocrine (18.3%), hearing (17.5%), renal (15.9%), and cardiovascular (15.9%) systems. Nearly one in five participants (19.8%) reported a second malignancy after ECD diagnosis, most commonly cutaneous squamous cell carcinoma (41.4%), followed by basal cell carcinoma, melanoma, and prostate cancer (10.3% each). Medical record review demonstrated excellent agreement with survey responses, confirming the diagnosis of ECD in all reviewed participants (41/41, 100%) and validating self-reported chronic health conditions with objective clinical data (50/50, 100%).

Conclusions: Adults living with ECD frequently develop chronic health conditions after diagnosis, including severe or life-threatening new-onset conditions in one-third of participants. These findings highlight the need for long-term survivorship care that extends beyond management of active disease and includes screening for late health effects. Future analyses will examine treatment-related risk factors and the timing of chronic health condition development to better define the long-term survivorship needs of this population.

Jacquelyn Elise Fitzgerald Fitzgerald, BS: No relevant conflicts of interest to declare.